Progression in ALK+ NSCLC After Frontline Therapy

preview_player
Показать описание
Describe the typical patterns of response and progression for patients with ALK-positive NSCLC [non–small cell lung cancer] treated with crizotinib, alectinib, and ceritinib.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Continuation of ceritinib 0:00:39

Continuation of ceritinib beyond disease progression in ALK-positive NSCLC

Case Study: Progression 0:06:04

Case Study: Progression on ALK Inhibitors in NSCLC

Brigatinib at Disease 0:05:19

Brigatinib at Disease Progression of ALK-Rearranged NSCLC

Treating ALK-Mutated NSCLC 0:08:11

Treating ALK-Mutated NSCLC With Disease Progression

Mutation Testing at 0:02:44

Mutation Testing at Progression of ALK-Rearranged NSCLC

ALK-positive NSCLC: CNS 0:01:40

ALK-positive NSCLC: CNS progression

Case Based Panel 0:11:54

Case Based Panel Discussion 2.5 Progression After ALK Inhibitors Is There a Role for Combination The

Case Based Panel 0:06:57

Case Based Panel Discussion 2019 ALK Positive Progression after Success on ALK Inhibitor

2020 TTF ALK 0:02:34

2020 TTF ALK SESSION QA PANEL Next Steps After Progression on Lorlatinib

NSCLC: How to 0:13:18

NSCLC: How to Handle ALK Resistance

Repeat Mutation Testing 0:04:13

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

Resistance Mechanisms in 0:02:08

Resistance Mechanisms in ALK-Rearranged NSCLC

Available Therapies for 0:03:13

Available Therapies for ALK-Rearranged NSCLC

First and Second 0:22:10

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

ALK Positive Lung 0:42:31

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

The Evolution of 0:04:05

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

Therapeutic Options at 0:05:38

Therapeutic Options at Progression of ALK-Rearranged NSCLC

Experience with Ceritinib 0:06:12

Experience with Ceritinib for ALK+ NSCLC

What to Do 0:08:22

What to Do After Progression on Immunotherapy and for Non-Driver NSCLC

ALTA II Trial 0:08:16

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

ALK 101 Part 1:10:58

ALK 101 Part 4: I Have Cancer Progression- Now What?!

Exploring Treatment Options 0:00:58

Exploring Treatment Options for Patients with ALK-Mutated Lung Cancer

2020 TTF ALK 0:03:06

2020 TTF ALK SESSION QA PANEL Progression on 2nd-Gen ALK Inhibitor if Biopsy Shows NO ALK Mutation

Understanding Lung Cancer 0:02:29

Understanding Lung Cancer Survival Rate